Measuring Treatment Response Following Induction Therapy in Patients with MM

EP: 1.Patient Profile 1: A 45-Year-Old with Transplant-Eligible Multiple Myeloma

EP: 2.Key Updates from the GRIFFIN Trial in Multiple Myeloma

EP: 3.Role of Transplant in Multiple Myeloma

EP: 4.Features of High-Risk Multiple Myeloma and Clinical Trial Landscape

Now Viewing

EP: 5.Measuring Treatment Response Following Induction Therapy in Patients with MM

EP: 6.Maintenance Therapy Considerations for Standard- and High-Risk MM

EP: 7.Experts Spotlight Some of The ‘Biggest Concerns’ In Multiple Myeloma

EP: 8.Patient Profile 2: A 79-Year-Old with Multiple Myeloma

EP: 9.MAIA Trial: DRd vs Rd in Transplant-Ineligible Patients with MM

EP: 10.Treatment Considerations for Transplant-Ineligible Patients with MM

EP: 11.CAR T-Cell Therapy in Transplant-Ineligible Patients with MM

EP: 12.Patient Profile 3: A 73-Year-Old with MM Treated with CAR T and Teclistamab

EP: 13.CAR T-Cell Therapy in the Treatment of Multiple Myeloma

EP: 14.MM: CAR T-Cell Therapy vs Bispecific T-Cell Engagers

EP: 15.BCMA Bispecific T-Cell Engagers in the Treatment of MM

EP: 16.Treatment Considerations for Bispecific Antibodies and Unmet Needs in MM

Transcript:

Al-Ola Abdallah, MD: Coming back to you, Nausheen. Patients, whether they get quadruple therapy or RVd [lenalidomide, bortezomib, dexamethasone] from community doctors, they’re going to go for transplant. They come to your office, I know there is a great system that you have, but you always look at adequate response. I have been in a lot of arguments about the type of response. I see it [with] community doctors; if they’re not happy with the response they completely change the treatment and delay sending the patients to transplant. What are your thoughts about that? What’s the definition of adequate response [where] you can tell the local oncologist, this cycle’s enough and we can move on for a transplant?

Nausheen Ahmed, MD: DrAbdallah, this is a very good question and often asked by most of the doctors who refer the patients. It kind of also segues into what you were talking about for MRD [minimal residual disease] testing. How deep do we want a response before we go into a transplant? And what’s the significance of getting a complete response [CR] before transplant vs a complete response after transplant? I think the studies are all over the place, so there’s no great data to support that you need a CR right before transplant. Although the general thought is that CR either right before the transplant, or early CR right after the transplant would translate into a better PFS [progression-free survival] and better outcomes. But again, the data are all over the place.

So, in general, how do we clinically approach this? Yes, I would ideally like to see some response. It doesn’t have to be a CR. It could be a partial response or a very good partial response, but I want some response. If I see that they’re resistant to the therapy, if they hardly had any response, then at times we have to switch gears and try another induction before we get them to transplant. But in general, as soon as we see any kind of response, we try to take them to transplant. Then, I think 1 other thing is that we also look at the bone marrow biopsy and percentage of plasma cells and take that into consideration, as well, when we are considering whether they’re ready for transplant.

Transcript edited for clarity.